Keytruda vs Imbruvica
Side-by-side drug price comparison from Medicare Part D data
Verdict
Imbruvica costs 43% less per claim than Keytruda ($10445.00 vs $18176.00). Imbruvica has a generic alternative available. Total Medicare spending: Keytruda at $7.2B vs Imbruvica at $5.7B.
| Metric | Keytruda | Imbruvica |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $18,176 | $10,445* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $7.2B | $5.7B |
| Total Claims | 398,000 | 548,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 28.6% | -8.7%* |
| Generic Available | No | Yes |
| Condition | Cancer | Cancer |
| Total Beneficiaries | 82,000 | 48,000 |
Imbruvica costs 43% less per claim than Keytruda ($10445.00 vs $18176.00). Imbruvica has a generic alternative available. Total Medicare spending: Keytruda at $7.2B vs Imbruvica at $5.7B.
Explore More
Comparing Keytruda and Imbruvica on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.